Natural isoflavonoids in invasive cancer therapy: From bench to bedside.
Lorena Cayetano-SalazarMonserrat Olea-FloresMiriam Daniela Zuñiga-EulogioCaroline Weinstein-OppenheimerGloria Fernández-TilapaMiguel Angel Mendoza-CatalánAna Elvira Zacapala-GómezJulio Ortiz-OrtizCarlos Ortuño-PinedaNapoleón Navarro-TitoPublished in: Phytotherapy research : PTR (2021)
Cancer is a public health problem worldwide, and one of the crucial steps within tumor progression is the invasion and metastasis of cancer cells, which are directly related to cancer-associated deaths in patients. Recognizing the molecular markers involved in invasion and metastasis is essential to find targeted therapies in cancer. Interestingly, about 50% of the discovered drugs used in chemotherapy have been obtained from natural sources such as plants, including isoflavonoids. Until now, most drugs are used in chemotherapy targeting proliferation and apoptosis-related molecules. Here, we review recent studies about the effect of isoflavonoids on molecular targets and signaling pathways related to invasion and metastasis in cancer cell cultures, in vivo assays, and clinical trials. This review also reports that glycitein, daidzein, and genistein are the isoflavonoids most studied in preclinical and clinical trials and displayed the most anticancer activity targeting invasion-related proteins such as MMP-2 and MMP-9 and also EMT-associated proteins. Therefore, the diversity of isoflavonoids is promising molecules to be used as chemotherapeutic in invasive cancer. In the future, more clinical trials are needed to validate the effectiveness of the various natural isoflavonoids in the treatment of invasive cancer.
Keyphrases
- clinical trial
- papillary thyroid
- cancer therapy
- cell migration
- public health
- squamous cell
- signaling pathway
- systematic review
- emergency department
- oxidative stress
- epithelial mesenchymal transition
- stem cells
- squamous cell carcinoma
- drug delivery
- chronic kidney disease
- newly diagnosed
- poor prognosis
- cell death
- ejection fraction
- endoplasmic reticulum stress
- prognostic factors
- single cell
- long non coding rna
- patient reported outcomes
- electronic health record
- cell therapy
- adverse drug